Pharmacovigilance Reporting Platform

What a Pharmacovigilance Reporting Platform is

Pharmacovigilance software manages drug safety after products reach patients. It receives adverse-event reports from healthcare professionals, patients, literature, and studies, codes them to standard terminologies, assesses seriousness and causality, and generates regulatory reports within required timelines.

Its defining pressure is time. Serious adverse events carry short reporting deadlines, and a missed or late report is a compliance failure with real consequences. The system must therefore track every case against its deadline from intake, and escalate cases that are approaching it.

Core features

Vigilance features move each case from intake to submission without losing deadline control.

• Multi-source case intake: Capture adverse-event reports from calls, web forms, literature, studies, and partner companies, deduplicating reports that describe the same event.
• Medical coding: Code adverse events and drugs to standard terminologies, with coding review workflows that keep coding consistent across cases.
• Seriousness and causality assessment: Assess each case for seriousness, expectedness, and causality, with structured assessment forms and reviewer sign-off.
• Deadline and workflow tracking: Track every case against regulatory reporting deadlines, with escalation for cases approaching or breaching their timeline.
• Regulatory submission generation: Generate submission files in the formats regulators require, with transmission tracking and acknowledgement reconciliation.
• Signal detection support: Aggregate cases by product, event, and population to support signal detection and safety review, with trend views for safety teams.

How it is built

Build intake and deadline control first, since a vigilance system that loses a deadline has failed regardless of its analytics.

1. Case model design: Define the adverse-event case model, coding standards, and assessment workflows, validated with drug-safety staff.
2. Intake and triage: Build multi-source intake, deduplication, and triage with deadline assignment from the moment a case is received.
3. Assessment workflows: Add coding, seriousness, and causality assessment with reviewer sign-off.
4. Submission generation: Add regulatory submission generation, transmission, and acknowledgement tracking.
5. Signal detection: Add aggregate analysis and signal-detection support once case handling is reliable.

Technology considerations

Vigilance platforms need rigorous case workflows, deadline engines, and submission formats that regulators accept. They must also handle sensitive patient data under privacy rules, with access controls that separate safety staff from commercial teams.

• Case workflow engine with deadline tracking and escalation
• Medical coding to standard terminologies with review workflows
• Regulatory submission generation and acknowledgement reconciliation
• Deduplication across intake sources
• Sensitive-data access controls separating safety from commercial use

Challenges to plan for

Vigilance systems fail on deadlines, coding consistency, and duplicate cases before they fail on design.

• Deadline discipline: Reporting clocks start at receipt, not at convenient processing times. Assign deadlines at intake and escalate automatically.
• Coding consistency: Inconsistent coding hides safety signals. Use coding review and standard terminologies rigorously.
• Duplicate cases: The same event reported twice inflates counts. Deduplicate across sources with human review for uncertain matches.
• Literature and partner intake: Reports arrive from literature and partners in varied formats. Budget for intake and mapping work per source.

What to scope before you build

Before scoping, list the products, markets, and report sources in the first release, and confirm which regulatory submission formats are required. Decide whether literature screening and partner-case exchange are in scope, since both add distinct intake workflows.

How it works in practice

A safety officer receives a serious adverse-event report by phone on a Friday afternoon, and the system starts the reporting clock at intake, assigning the case, its deadline, and its coding tasks immediately. Over the weekend, the case is coded, assessed for seriousness and causality, and reviewed, and the regulatory submission is generated and transmitted before the deadline, with the acknowledgement reconciled on Monday. A duplicate report of the same event arriving from a partner company is matched and merged rather than counted twice. Success is measured by on-time submission rate, duplicate rate, and coding consistency, because in pharmacovigilance, a late or double-counted case is a compliance failure with a patient's story behind it.

Frequently asked questions